Intellia’s CRISPR Gene Therapy for Rare Disease Advances in Phase 3 Trial, Sun Pharma to Acquire Organon for $11.75B

Intellia’s CRISPR Gene Therapy Shows Promise in Phase 3 Trial for Rare Disease

Intellia Therapeutics announced that a single dose of its gene editing treatment, lonvo-z, dramatically reduced swelling attacks in patients with hereditary angioedema (HAE) during a Phase 3 trial. The results pave the way for potential regulatory approval, according to STAT.

The therapy would become the second CRISPR-based medicine approved in the U.S., following Vertex Pharmaceuticals’ sickle cell treatment Casgevy. Intellia has already initiated a rolling submission with the FDA, marking a significant milestone as the first in vivo treatment—meaning it edits patient DNA directly within the body.

The success of lonvo-z hinges on its "one-and-done" approach, which could influence patient and physician adoption. HAE, a rare genetic disorder, affects approximately 20,000 patients in the U.S. and Europe. The condition has seen an influx of new treatments in recent years, reflecting growing innovation in rare disease therapies.

Sun Pharmaceutical to Acquire Organon in $11.75 Billion Deal

Sun Pharmaceutical has agreed to acquire Organon in a deal valued at $11.75 billion, positioning the Indian drugmaker as a top global player in women’s health, The Wall Street Journal reports.

Sun Pharmaceutical, known for its generics and ranking among India’s largest pharma companies by market cap, will finance the acquisition through a combination of internal cash reserves and external bank financing. Organon, originally spun off from Merck, boasts a portfolio of over 70 products spanning women’s health and general medicines, including biosimilars. These products are commercialized across 140 countries.

Organon reported $6.2 billion in revenue for 2025. The acquisition will propel Sun Pharmaceutical into the top 25 global pharmaceutical companies, with projected revenues of $12.4 billion.

Key Takeaways

• Intellia’s lonvo-z could become the second CRISPR-based approved treatment after Vertex’s Casgevy.
• The Phase 3 trial results for lonvo-z show a significant reduction in swelling attacks for HAE patients.
• Sun Pharmaceutical’s $11.75 billion acquisition of Organon will expand its global footprint in women’s health.
• The deal will elevate Sun Pharmaceutical to the top 25 global pharma companies with $12.4 billion in revenue.